Department of Health and Human Services February 17, 2021 – Federal Register Recent Federal Regulation Documents
Results 1 - 7 of 7
Notice of Temporary Exception From Expulsion of Unaccompanied Noncitizen Children Pending Forthcoming Public Health Determination
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS) announces a temporary exception from expulsion for unaccompanied noncitizen children to its Order issued October 13, 2020 suspending the right to introduce certain persons from countries where a quarantinable communicable disease exists.
Cellular, Tissue and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue and Gene Therapies Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on scientific issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Draft NTP Technical Reports on Sodium Tungstate Dihydrate, Di-n-butyl phthalate, and Di(2-ethylhexyl) Phthalate; Availability of Documents; Request for Comments; Notice of Peer-Review Meeting
The National Toxicology Program (NTP) announces the availability of the Draft NTP Technical Reports on sodium tungstate dihydrate, di-n-butyl phthalate, and di(2-ethylhexyl) phthalate scheduled for peer review. The peer-review meeting will be held remotely and will be available to the public for veiwing. Oral and written comments will be accepted; registration is required to access the virtual event and to present oral comments. Information about the meeting and registration is available at https://ntp.niehs.nih.gov/go/ 36051.
Determination That NYMALIZE (nimodipine), Oral Solution, 3 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, the Agency, or we) has determined that NYMALIZE (nimodipine), oral solution, 3 milligrams (mg)/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for nimodipine, oral solution, 3 mg/mL, if all other legal and regulatory requirements are met.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
